Impact of rapid multigene assays with short turnaround time (TAT) on the development of precision medicine for non-small cell lung cancer (NSCLC)

Background: A variety of oncogene drivers have been identified in NSCLC and molecularly-stratified precision medicine has led to improved survival in advanced NSCLC. Next-generation sequencing (NGS)-based testing is utilized to detect actionable gene alterations; however, the TAT of NGS is often too long to translate into clinical decision making. Thus, rapid multi-gene testing alternatives are needed. Conclusions: Both the 9-in-1 test and Genexus/OPA had short TATs (3−4 days), high success rates (96−98%) and good concordance (95−98%) compared with another NGS assay (OCA). These rapid multi-gene assays highly contributed to enabling precision medicine and the development of targeted therapies for advanced NSCLC. READ ARTICLE

Journal of Clinical Oncology DOI:10.1200/JCO.2021.39.15_suppl.9094

Authors: Shingo Matsumoto, Takaya Ikeda, Kiyotaka Yoh, Akira Sugimoto, Terufumi Kato, Kei Kunimasa, Atsushi Nakamura, Ichiro Nakachi, Shoichi Kuyama, Jun Sakakibara-Konishi, Haruko Daga, Eiji Iwama, Kageaki Taima, Naoki Furuya, Kaname Nosaki, Hiroki Izumi, Yoshitaka Zenke, Koichi Goto

Conference PaperKirk SmithMay 28, 2021Rapid multigene assays, turnaround time (TAT), precision medicine, non-small cell lung cancer (NSCLC)

Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices

Background: Given the importance of molecular testing and targeted therapy for mNSCLC, the MYLUNG (Molecularly Informed Lung Cancer Treatment in a Community Cancer Network) consortium pragmatic study assessed real-world biomarker testing rates and turnaround times (TAT) within The US Oncology Network of over 1,000 providers across the United States. Conclusions: This real-world study showed that most pts received at least one biomarker test prior to 1L, but <50% received all 5 tests. NGS testing occurred in <50% of pts but increased over the periods examined. Median time from dx to 1L therapy was about 5 weeks and TAT from orders to results about 2 weeks. Analyses by histology and other trends will be reported. These data will be compared to the next phase of the MYLUNG study, which will evaluate contemporary ordering practices and TATs prospectively. READ ARTICLE

Journal of Clinical Oncology DOI:10.1200/JCO.2021.39.15_suppl.9004

Authors: Nicholas J. Robert, Esmond D. Nwokeji, Janet L. Espirito, Liwei Chen, Mandar Karhade, Makenzi Colleen Evangelist, Alexander I. Spira, Marcus A. Neubauer, Susie A. Bullock, Robert L. Coleman, on behalf of MYLUNG Consortium Collaborators: The U.S. Oncology Network and sponsors

Conference PaperKirk SmithMay 28, 2021Biomarker, tissue, metastatic non-small cell lung cancer (mNSCLC), oncology, turnaround time (TAT)